Category: elsevier

More black marks against unapproved protein touted as miracle cure

clinical immunologyA protein which is sold online as a cure for everything from autism to cancer and the focus of multiple retracted papers has earned more black marks: The UK government’s Medicines and Healthcare Products Regulatory Agency has issued a warning about its use after discovering problems in the factory, and a journal has removed the last author from a paper touting its benefits in HIV.

The protein, vitamin D-binding protein-derived macrophage activating factor (GcMAF), is supposedly a natural activator of macrophages. The website GcMAF.eu continues to hawk the results of treatment, while the Anticancer Fund has been pushing journals to correct the record on GcMAF. Continue reading More black marks against unapproved protein touted as miracle cure

Rebirth of ovary article prompts retraction from OB lit

ejoglogoThe European Journal of Obstetrics & Gynecology and Reproductive Biology has retracted a 2014 paper on polycystic ovary syndrome for self-plagiarism.

In the notice, the journal states that “significant portions” of the findings in “Association of anti-Mullerian hormone and small-dense low-density lipoprotein cholesterol with hepatosteatosis in young lean women with and without polycystic ovary syndrome” already appeared in another paper. Three authors appear in both publications, all based at the University of Ufuk (don’t think too hard about that name) in Ankara, Turkey. Continue reading Rebirth of ovary article prompts retraction from OB lit

Materials science paper yanked over data pilfering

materials lettersMaterials Letters has withdrawn an article in press after the editor found out the first author, Yan Li, had taken all the data without permission.

According to the notice, the senior author told the journal that the data came from the lab Li used to work in at the University of Rome Tor Vergata, but the P.I. in Italy didn’t know about the paper.

From the notice: Continue reading Materials science paper yanked over data pilfering

First cut is the deepest: paper on incisional hernia sliced for duplication

jamcolsurgeonsThe authors of a 2014 paper in the Journal of the American College of Surgeons about incisional hernia have lost their article for being a duplicate submission.

The paper, “Impact on Quality of Life of Using an Onlay Mesh to Prevent Incisional Hernia in Midline Laparotomy: A Randomized Clinical Trial,” came from a group at the Parc Tauli University Hospital, part of the Universitat Autònoma de Barcelona, in Spain.

By duplicating another paper, the authors (three of which appear to be listed on both papers) committed “a severe abuse of the scientific publishing system,” according to the retraction notice: Continue reading First cut is the deepest: paper on incisional hernia sliced for duplication

Heart study bleeds into three papers, one retracted and one withdrawn

janWith the increasingly hectic pace of modern life, everybody is always on the look out for time-saving tricks and tips.

Scientists at the National University of Singapore and the Hong Kong Polytechnic University certainly found one, but we really can’t recommend it: doing one randomized controlled trial (RCT) with several outcomes, and publishing them as three separate 2014 papers with “considerable overlap.”

So far, one paper has been retracted, and another withdrawn.

Continue reading Heart study bleeds into three papers, one retracted and one withdrawn

“Genuine error” sees expression of concern for vision loss paper

elsevierA duplicated figure has resulted in an expression of concern for a paper in the American Journal of Pathology on a treatment for ocular neovascularization, which causes vision loss.

According to the notice, the corresponding author, David Shima, now at University College London, brought his concern to the journal. He called it a “genuine error” and stated that all the findings had been reproduced.

Unfortunately, Shima claimed the original data are missing, because the institution that owned the information — Eyetech Research Center — has “since gone through several acquisitions.”

Ocular neovascularization occurs when growth signals in the eye stimulate the creation of many new blood vessels. Over time these blood vessels break, causing bleeding and scarring that limits vision. This is called “wet” macular degeneration.

The scientists found that giving patients drugs to limit two different growth factors at the same time is more effective than one at stopping the progression of AMD. This combination method is in stage three clinical trials, though with different drugs than the authors used here.

The paper, published in 2006, has been cited 130 times, according to Thomson Scientific’s Web of Knowledge. Here’s the EoC for “Inhibition of Platelet-Derived Growth Factor B Signaling Enhances the Efficacy of Anti-Vascular Endothelial Growth Factor Therapy in Multiple Models of Ocular Neovascularization”:

Continue reading “Genuine error” sees expression of concern for vision loss paper

Unspecified questions earn central line study an expression of concern

ajicThe American Journal of Infection Control has issued an expression of concern for a paper looking at ways to reduce infections associated with central venous catheters, or central lines.

The catheters are placed directly into a large vein and end close to the heart, allowing long-term access for medication or fluid administration. According to the CDC, infections associated with central lines cause thousands of deaths and cost billions of dollars every year.

Here’s the abstract for “Comparison of central line-associated bloodstream infection rates when changing to a zero fluid displacement intravenous needleless connector in acute care settings“: Continue reading Unspecified questions earn central line study an expression of concern

Conflict of interest, figure issues net retraction for cancer paper

am j pathologyTwo major problems sunk this cancer paper.

For one, many of the images were copied from another paper. In addition, one of the authors did not disclose that he was the president of a related company, nor that his company provided reagents for the experiments.

It’s not clear when the paper was published, but The paper was published on October 16, 2014, and a withdrawal notice went up on January 16, 2015. Here’s the retraction for “Enhanced Detection and Phenotypic and Karyotypic in Situ Characterization of Circulating Tumor Cells”: Continue reading Conflict of interest, figure issues net retraction for cancer paper

Lancet retracts and republishes cardiology paper with admirable notice

logo_lancetOne of the papers from a massive heart disease study in China, published in the Lancet, has been retracted and republished after the authors noticed a statistical error.

The article, by authors from Peking Union Medical College in China, Yale University, and elsewhere, presented the results of the China PEACE-Retrospective Acute Myocardial Infarction Study, part of a national initiative to study and improve care for cardiac problems. After being posted online on June 24, 2014, the authors noticed that they’d incorrectly weighed one of the cities in their calculations, which threw off a number of national estimates.

After the corrections were made, the paper was peer-reviewed again, and reviewers stated that despite the mistakes, the original conclusions were sound.

Today is a banner day on Retraction Watch: This is our second excellent example of transparency in 24 hours, and therefore the second entry in our “doing the right thing” category. An editorial lays out exactly what happened, including a timeline, allowing scientists to feel confident they’re basing the next research step on solid and accurate data. (We also appreciate the hat tip to the Committee on Publication Ethics retraction guidelines, which we often send out to editors of bad notices as a gentle reminder.)

Here’s the notice for “ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data”: Continue reading Lancet retracts and republishes cardiology paper with admirable notice

Fraud retraction appears for deceased Maryland dental researcher

osomoporeA former dental researcher at the University of Maryland, Baltimore, has lost a 2009 paper in the journal Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology for fabricating his data on an NIH-funded study.

The researcher, Mark A. Scheper, is not identified in the retraction notice as the person implicated in the university investigation. However, one of his co-authors confirmed his involvement. Scheper died in January 2014 at age 45 of natural causes, according to the Maryland State Medical Examiner.

The article was titled “The oncogenic effects of constitutive Stat3 signaling in salivary gland cancer cells are mediated by survivin and modulated by the NSAID sulindac.” It appeared online in March 2009, and has been cited six times, according to Thomson Scientific’s Web of Knowledge.

According to the abstract: Continue reading Fraud retraction appears for deceased Maryland dental researcher